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S U M M A R Y
Objectives: We studied the growth and development of children prenatally exposed to telbivudine used
to treat chronic hepatitis B virus (HBV) infection in their mothers.
Methods: Maternal abnormalities during pregnancy and delivery and infant congenital anomalies,
physical development status, developmental quotient (DQ), HBV vertical transmission status, and HBV
vaccination outcomes of 54 infants were evaluated (2010–2013).
Results: No fetal abnormalities were observed during pregnancy or delivery. Postpartum, three infants
(5.56%) had abnormalities: ankyloglossia, cutaneous hemangioma, and vaginal canal leak. Height and
weight were within the normal range at birth and at 6 weeks, but were higher than the reference at
12 months (p < 0.05). Body mass index increased gradually with age (p < 0.05). DQ scores were normal
(84.81%, 229/270) in 37 children (68.52%), abnormal or suspicious for a developmental delay (15.19%,
41/270) in 17 children (31.48%), and indicated a developmental delay (4.07%, 11/270) in seven children
(12.96%). There were no signiﬁcant differences in developmental delay between children prenatally
exposed to telbivudine and controls (p > 0.05). HBV vertical transmission was successfully blocked in all
infants. The effective HBV vaccination rate was 98.15% (53/54).
Conclusions: The growth and development of children prenatally exposed to telbivudine was normal,
indicating that telbivudine treatment during pregnancy is safe and effective.
 2015 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Chronic hepatitis B virus (HBV) infection is an infectious disease
that affects approximately two billion people worldwide; in
addition, 350 million people are chronic carriers of the virus.1
Furthermore, the prevalence of hepatitis B surface antigen (HBsAg)
positivity among fertile women in some highly epidemic areas,
such as Africa and Asia, can be as high as 9.2–15.5%, and in China
the prevalence is 11.0%. Chronic HBV-infected fertile women may
require antiviral treatment during pregnancy.1–4
Telbivudine (L-deoxythymidine; LdT) is an approved oral
nucleoside analog (NA) used to inhibit HBV within the cytoplasm
that has been assigned to pregnancy category B by the US Food* Corresponding author. Tel.: +86 10 59616626; fax: +86 10 59718620.
E-mail address: Ying_116sh@sohu.com (Y. Shen).
http://dx.doi.org/10.1016/j.ijid.2014.09.002
1201-9712/ 2015 Published by Elsevier Ltd on behalf of International Society for Infect
creativecommons.org/licenses/by-nc-nd/3.0/).and Drug Administration; therefore, it can be used during
pregnancy. For some chronic HBV-infected women who become
pregnant during the NA treatment period and for whom
conservative treatment is not recommended, discontinuing the
antiviral treatment during pregnancy would result in possible
exacerbation of hepatic disease and threaten the safety of both the
mother and infant.4–6 Therefore, NA treatment in these women
should be used during pregnancy, either in late pregnancy only or
throughout the entire pregnancy. The risk of HBV perinatal
transmission is highest in women with high levels of viremia,7,8
and some pregnant women with a high HBV viral load take an NA
to lower the risk of HBV vertical transmission, usually commencing
in the third trimester.9,10 All of the fetuses in these pregnancies
experience intrauterine exposure to the NA, which may affect fetal
development.
Lamivudine and LdT, as NAs, signiﬁcantly reduce viral loads
and vertical transmission and have favorable safety proﬁles inious Diseases. This is an open access article under the CC BY-NC-ND license (http://
H. Zeng et al. / International Journal of Infectious Diseases 33 (2015) 97–10398pregnancy.11–16 However, there are very few reports regarding the
growth and development of children prenatally exposed to LdT.
The present study aimed to evaluate the growth and development
of children exposed to LdT in the fetal period to provide insights
into the efﬁcacy and safety of LdT use in the perinatal period.
2. Materials and methods
2.1. Patients
From January 1, 2010 to May 1, 2013, 54 children delivered to
mothers with chronic HBV infection who received LdT treatment
during their pregnancy at Beijing Ditan Hospital were enrolled in
this study. Three mothers had experienced abnormalities during a
previous pregnancy: hydatidiform mole in two mothers and
sebaceous adenoma resection in one mother. Twenty mothers
continued existing LdT treatment throughout their pregnancy
because they could not stop treatment while pregnant. Nine
mothers had received another NA or interferon treatment but later
had virological breakthrough and liver function rebound and
switched to LdT treatment in pregnancy. Twenty-ﬁve mothers had
never taken any NA treatment, but used LdT in late pregnancy at a
gestational age >28 weeks because of the results of laboratory
tests (alanine aminotransferase <2 times the normal upper limit of
the reference range and HBV DNA >1  105 copies/ml). All mothers
were chronic hepatitis B patients without compensated cirrhosis.
None of the mothers were co-infected with hepatitis C virus,
hepatitis delta virus, HIV, syphilis, toxoplasmosis, rubella, cyto-
megalovirus, Epstein–Barr virus, or herpes simplex virus, and none
had an endocrine or metabolic disease, organ failure, or were drug
abusers. All of the mothers underwent routine pregnancy
examinations and took nutritional supplements during pregnancy,
including folic acid during early pregnancy to prevent embryonic
neural tube defects. Demographic characteristics and basic clinical
information, including HBV infection status and treatment history,
are summarized in Table 1. The mothers and their infants were
divided into two groups: those taking LdT during their entire
pregnancy (early-pregnancy treatment group) and those taking
LdT only during late pregnancy (late-pregnancy treatment group).
An additional 54 children delivered to mothers with chronic
HBV infection who did not receive LdT treatment during their
pregnancy were selected as controls. The children’s parents were
matched by age and educational level. In addition, a congenital
anomalies observation control group included infants born to
mothers with chronic HBV infection who did not receive NA
treatment during their pregnancy at Beijing Ditan Hospital
between January 1, 2010 and December 31, 2010 (n = 2747) and
between January 1, 2011 and December 31, 2011 (n = 2567).Table 1
Clinical information of mothers treated with telbivudine during pregnancy
Observed population
(N = 54)
Average age, years 30.45  3.82
Primipara, n (%) 25 (46.29)
Cirrhosis, n (%) 0 (0)
HBeAg positivity rate, n (%) 40 (74.07)
HBV DNA >105 copies/ml in early pregnancy, n (%) 25 (46.30)
HBV DNA >105 copies/ml before delivery, n (%) 4 (7.41)
Treatment before pregnancy, n (%)
Naive 25 (46.29)
ADV 5 (9.26)
LAM!ADV 4 (7.41)
IFN + LdT 1 (3.70)
LdT 20 (37.03)
ADV, adefovir dipivoxil; HBeAg, HBV e antigen; HBV, hepatitis B virus; IFN,
interferon; LAM, lamivudine; LdT, telbivudine.2.2. Methods
All mothers underwent routine screening tests, including
assessments of liver function and HBV serology (HBV markers
and HBV DNA) every 12 weeks. All adverse events that occurred
during pregnancy and delivery were recorded.
Our evaluation of the growth and development of all infants
started at delivery and continued for at least 12 months.
Assessments included the occurrence of adverse events in the
infants during different periods, congenital and developmental
anomalies, physical development status (weight and height),
developmental quotient (DQ), HBV vertical transmission status,
and HBV vaccination outcomes.
The infants’ clinical data, including average gestational age,
delivery mode, Apgar score, physical development status, and
adverse events during the neonatal period and infancy, were
recorded. The physical development status of the infants was
evaluated at three time points: immediately after birth and at
6 weeks and 12 months of age.
Congenital and developmental anomalies were identiﬁed
by physical examination, hearing screening, and laboratory
tests, in addition to renal screening, if necessary, for at least
24 months.
The neurodevelopment of infants was evaluated by the DQ
using the Gesell Developmental Schedules (GDSs), which include
reﬂexes and reactions (voluntary, spontaneous, or learned), as
well as postural reactions, locomotion, and coordination, con-
structive ability (which is inﬂuenced by motor development), and
visible and audible communication; individual reactions regard-
ing people and stimulations (depending mainly on the tempera-
ment of the child and the surroundings) were also evaluated. The
results are expressed as scores for the ﬁve domains assessed:
adaptability, gross motor skills, ﬁne motor skills, language, and
sociability. Each child was assigned a DQ in each of the ﬁve areas,
resulting in a total of 270 items for the 54 children. A score <85
indicates a suspicion of developmental delay, and a score <75
indicates a developmental delay.4 Testing was conducted by
trained DQ test professionals to maximize reliable assessment
and valid interpretation, minimizing both inter- and intra-
examiner variability.
Liver function, HBV serology, and HBV DNA of infants were
measured twice: at birth and 1 month after the HBV vaccinations
were completed (7–8 months). The rate of blocking vertical
transmission of HBV and the outcomes of HBV vaccination were
conﬁrmed and analyzed.
2.3. Laboratory tests
Liver function and HBV serology were tested in the hospital’s
clinical laboratory. HBV DNA was detected with a real-time PCR
ampliﬁcation kit (Kehua Biological Company, Shanghai, China),
which can detect HBV DNA levels as low as 500 copies/ml. HBV
markers were detected using ELISA kits (Abbot Laboratories, North
Chicago, IL, USA) on an ARCHITECT i2000 automatic immunoassay
analyzer (Abbott), in accordance with the manufacturer’s instruc-
tions.
Hearing screenings were performed with the Echo-Screen
(Madsen Company, Germering, Germany).
Peripheral blood samples were spotted onto ﬁlter paper, and
the specimens were sent to the Beijing Neonatal Diseases
Screening Center to rule out congenital phenylketonuria and
hypothyroidism by liquid chromatography tandem mass
spectrometry detection. Five types of congenital disease
(hearing defects, congenital heart disease, congenital hip
dislocation, congenital hypothyroidism, and phenylketonuria)
were assessed.
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The statistical analysis was performed using SPSS version 18.0
(SPSS Inc., Chicago, IL, USA). Measurement data are expressed as
the mean and standard deviation and were compared with analysis
of variance or t-tests. Fisher’s exact test was used for the
comparison of rates. A p-value of <0.05 was considered statisti-
cally signiﬁcant.
3. Results
3.1. Maternal baseline characteristics and adverse events during
pregnancy
The average LdT treatment times in the early-pregnancy
treatment and late-pregnancy treatment groups were
38.05  1.54 weeks (range 36–41 weeks) and 10.43  1.02 weeks
(range 9–11 weeks), respectively.
No developmental retardation was found in any fetus with
ultrasound monitoring during pregnancy. One mother underwent
in vitro fertilization with the transfer technique and delivered a
female infant. Another mother had a threatened abortion, but
symptoms of miscarriage disappeared after aggressive treatment.
The most common adverse events for mothers during
pregnancy were gestational diabetes (16/54, 29.62%), viral
hepatitis (7/54, 12.96%), pregnancy cholestasis syndrome (6/54,
11.1%), and premature rupture of the membranes (4/54, 7.41%).
Other adverse events included hyperemesis gravidarum, moder-
ate-to-severe anemia (hemoglobin level <9 g/l), edema, polyhy-
dramnios, vulvar abscess, and common cold.
In the late-pregnancy treatment group, 20 of 25 mothers had
HBV DNA >1  105 copies/ml. The viral load of all of the cases
decreased after LdT treatment, and 11 cases had no detectable HBV
viremia at antepartum testing (HBV DNA <500 copies/ml). In the
early-pregnancy treatment group, 17 of 29 cases had HBV DNA
>5  102 copies/ml in early pregnancy, and the viral load decreased
after LdT treatment; at antepartum testing, 27 cases had no HBV
viremia and two had a viral load of 5.75  102 copies/ml.
3.2. Clinical characteristics and adverse events during the neonatal
period
The average gestational age of the infants was 39  1.41 weeks,
with one neonate delivered preterm at 36 weeks without complica-
tions. Sixteen of the 54 infants were born by cesarean delivery.
Normal Apgar scores at delivery were recorded, with only one
neonate with blue asphyxia and an Apgar score of 7; the blue asphyxia
symptoms disappeared after aggressive treatment, and the subse-
quent 5- and 10-min Apgar scores were normal.
The most common adverse events for infants were nuchal cord
(13/54, 24.07%) and premature rupture of the membranes (4/54,
7.41%). Other adverse events included extremely long umbilicalTable 2
Height and weight of children prenatally exposed to telbivudine administered to treat
Height, cm (N = 54) 
At birth At 6 weeks At 12 m
Average 50.42  1.03 57.75  2.37 77.98 
Highest 53 63 81.7 
Lowest 47 53 70 
Average, boys 50.67  1.12 57.63  2.72 78.5  
Average, girls 49.89  1.13 57.8  2.01 77.93 
Normal cases (%) 53 (98.15) 50 (92.59) 53 (98
* P < 0.05.cord and caput succedaneum. There were no fetal developmental
abnormalities reported around the time of delivery.
3.3. Congenital dysplasia and adverse event monitoring
All 54 infants were followed up for more than 12 months,
11 were followed up for more than 2 years, and one was followed
up for more than 3 years. None of the infants had abnormal
hearing, congenital phenylketonuria, hypothyroidism, congenital
heart disease, or congenital hip dislocation. Three infants in the
early-pregnancy treatment group had abnormalities postpartum:
one infant with ankyloglossia without delayed language develop-
ment whose parents planned to arrange surgery when he was
2 years old and one infant with a 3  3-cm cutaneous hemangioma
on the right foot after 4–5 months of topical therapy that
disappeared when the infant was 7 months old. Another infant
with vaginal canal leak underwent successful surgery when the
infant was 1 month old. Other infants showed no signs of abnormal
congenital dysplasia. Thus, the abnormality rate of all infants in
this study was 5.56% (3/54). There were no signiﬁcant differences
in the abnormality rates between the children observed in this
study and the controls in 2010 (72/2747, Chi-square = 1.569,
p = 0.403) or 2011 (50/2567, Chi-square = 3.46, p = 0.090).
The most common adverse events for infants younger than
6 weeks old were eczema (14/54, 25.92%) and hypocalcemia (11/
54, 20.37%). The most common adverse events for infants younger
than 12 months old were respiratory tract infection (7/30, 23.33%),
diarrhea (5/54, 9.25%), and eczema (4/54, 7.41%). Other adverse
events in infants included nasal obstruction, neonatal pneumonia,
myocardial damage, newborn infection, and inguinal hernia. One
case in the late-pregnancy treatment group had language
retardation; this patient had delayed language abilities without
a nervous disorder.
3.4. Physical development status during infancy
Height and weight increased gradually with age during the ﬁrst
12 months (Table 2). The physical development status of 98.15% of
the neonates was in the normal range; two infants had
macrosomia without complications such as hypoglycemia. There
were no small-for-gestational-age neonates. The height (53 cm) of
only one female neonate was higher than the reference range.
There were no signiﬁcant differences between the average weights
and heights of neonates and the reference values of the World
Health Organization (WHO) 2006 child growth standards
(p > 0.05).17 There were no signiﬁcant differences between the
early-pregnancy treatment and late-pregnancy treatment groups
in physical development status or adverse events during the
neonatal period (p > 0.05).
No growth retardation cases were observed during the infancy
period. The average height and weight of the infants were in the
normal range at delivery and at 6 weeks of age, but were higher
than the reference range at 12 months of age (p < 0.05). The chronic hepatitis B in their mothers
Weight, kg (N = 54)
onths At birth At 6 weeks At 12 months
 2.25 3.31  0.82 5.15  0.58 10.2  0.91
4.25 6.4 11.6
2.65 3.95 7.5
1.52* 3.58  0.30 5.29  0.35 10.50  1.02*
 2.34* 3.06  0.65 5.09  0.60 10.24  0.46*
.15) 54 (100) 53 (98.15) 54 (100)
Table 3
Body mass index of children prenatally exposed to telbivudine administered for the treatment of chronic hepatitis B in their mothers
Age BMI (N = 54)
Normal cases (%) Average Highest Lowest Early-pregnancy
treatment group (n = 29)a
Late-pregnancy
treatment group (n = 25)b
At birth 54 (100%) 13.49  1.04* 15.1 11.2 13.41  1.61 13.62  2.21
6 weeks 53 (98.15) 15.22  1.49* 18.85 11.05 15.84  1.65 14.19  3.12
12 months 53 (98.15) 16.69  1.54* 21.22 14.63 16.55  1.36 16.82  1.22
BMI, body mass index.
a Early-pregnancy treatment group: children whose mothers took telbivudine during their entire pregnancy.
b Late-pregnancy treatment group: children whose mothers took telbivudine only during late pregnancy.
* P < 0.05.
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normal range at 6 weeks of age. The heights (63 cm) of two infants
were higher than the reference value, one infant (6.4 kg) was
heavier than the reference. The other two infant’s heights (one was
54.5 cm and the other was 6.4 cm) were lower than the reference
value at 6 weeks of age. The physical development status of 98.15%
of the infants was in the normal range at 12 months of age; only
one infant (81.7 cm) was taller than the reference.
The body mass index (BMI) of both groups increased gradually
with age (p < 0.05) (Table 3). BMI was in the normal range for the
majority of the children; only one male infant’s BMI (11.05 kg/m2) atFigure 1. Development quotient (DQ) scores of children prenatally exposed to telbivudine
was assessed for the ﬁve DQ scores, including adaptability, gross motor skills, ﬁne mot
indicates a developmental delay and a score 75 and <85 indicates a suspicion of a de
prenatally exposed to telbivudine were <75, indicating a developmental delay.6 weeks was lower than the 95% reference range, and one infant’s
BMI (21.22 kg/m2) at 12 months was higher than the 95% reference
range. There were no signiﬁcant differences in BMI between the
early-pregnancy treatment and late-pregnancy treatment groups
during infancy (p > 0.05).
3.5. DQ monitoring
The normal DQ was 100  15 (Figure 1); 84.81% (229/270) of the
DQ scores in 68.52% (37/54) of the children were normal. In 17
(31.48%) children, 15.19% (41/270) of the DQ scores indicated either a administered for the treatment of chronic hepatitis B in their mothers. Each patient
or skills, language, and sociability, totaling 270 items for 54 patients. A score <75
velopmental delay. Eleven items (4.07%, 11/270) for seven children (12.96%, 7/54)
Table 4
Development quotient (DQ) of children prenatally exposed to telbivudine administered for the treatment of chronic hepatitis B in their mothers
DQ (N = 54) Highest Lowest Average
Total (N = 54) Early-pregnancy treatment
group (n = 29)a
Late-pregnancy treatment
group (n = 25)b
Adaptability 117 75 94.64  10.30 95.97  10.78 93.12  9.74
Gross motor skills 132 70 99.09  13.94 100.17  14.25 97.84  13.76
Fine motor skills 124 69 99.35  11.25 98.58  11.93 101.24  10.58
Language competence 127 58 95.17  12.65 94.25  12.50 96.21  12.70
Social skills 126 73 100.44  14.79 100.34  14.42 100.56  15.52
a Early-pregnancy treatment group: children whose mothers took telbivudine during their entire pregnancy.
b Late-pregnancy treatment group: children whose mothers took telbivudine only during late pregnancy.
Table 5
Development quotient (DQ) of children prenatally exposed to telbivudine, compared with controls
Development quotient Number Patients Controls Chi-square p-Value
Developmental delay
DQ <75, %
Cases (N = 54) 7 (12.96) 2 (3.70) 3.03 0.16
DQ test items (n = 270) 11 (4.07) 4 (1.48) 3.36 0.11
Suspicion of developmental delay
75  DQ < 85, %
Cases (N = 54) 10 (18.52) 3 (5.55) 4.29 0.07
DQ test items (n = 270) 30 (11.11) 9 (3.33) 12.19 0.00
Abnormality in all
DQ <85, %
Cases (N = 54) 17 (31.48) 5 (9.26) 8.22 0.008
DQ test items (n = 270) 41 (15.19) 13 (4.81) 16.13 0.00
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(4.07%, 11/270) items in seven children (12.96% 7/54) who were
prenatally exposed to LdT were <75, indicating a developmental
delay. Thirty (7.04%, 30/270) items in 10 children (18.5% 10/54) were
in the suspiciously low range, indicating a suspicion of developmental
delay. The abnormally low scores were spread throughout the GDS
regions. One child had abnormally low scores in ﬁve DQ regions; the
ﬁne motor and adaptive abilities of this infant were deemed
developmentally delayed, and the other three DQ regions were
considered suspicious for a developmental delay.
There were no signiﬁcant differences in the ﬁve DQ scores
between the early-pregnancy treatment and late-pregnancy
treatment groups (p > 0.05) (Table 4). There were also no
signiﬁcant differences in developmental delay between those
children prenatally exposed to LdT and the controls (p > 0.05).
There were differences in the combined developmental delay and
suspicion of developmental delay between those children prena-
tally exposed to LdT and the controls (p < 0.05) (Table 5).
3.6. Prevention of mother-to-infant transmission and HBV
vaccinations
Liver function, HBV serology, and HBV DNA of the children were
evaluated at 7–8 months of age. No HBsAg-positive cases were
found, and vertical transmission was successfully blocked in
54 infants, for a blocking rate of 100%. A quantitative HBV surface
antibody (anti-HBs) test revealed effective vaccination (anti-HBs-
positive) in 53 infants in our study, with maximum and minimum
titers of 1000 and 127.21 mIU/l, respectively. The effective
vaccination rate of the infants in our study was 98.15% (53/54),
with no differences between the early-pregnancy treatment and
late-pregnancy treatment groups (p > 0.05). Only one infant
whose parents were both chronic HBV-infected and whose mother
had taken LdT throughout her pregnancy was anti-HBs-negative,
and the vaccination failed. After enhanced HBV vaccination at age
8 months, the infant’s anti-HBs titer increased to 127.8 mIU/ml at
12 months of age.4. Discussion
Although there have been a number of studies regarding the
safety of LdT treatment in pregnancy,11–16 very few have been
reported regarding the growth and development of children
delivered to chronic HBV-infected women treated with LdT. The
abnormality rate in all of the infants in the present study was
similar to that of infants born to mothers without or with HBV
infection (5.1–6.3% and 7.2–10%, respectively) in previous
reports.18–20
LdT treatment is reportedly effective for blocking HBV mother-
to-infant transmission (MTIT). For infants born to hepatitis B e
antigen (HBeAg)-positive mothers, vertical transmission was not
blocked in 7–16.3% of women with a high HBV viral load during
pregnancy faced with a high risk of MTIT, even after receiving
passive–active immunoprophylaxis with hepatitis B immunoglob-
ulin and three doses of hepatitis B vaccine.21 In a previous study,
none of the infants whose mothers received LdT had immuno-
prophylaxis failure, whereas 8.6% of the infants of control mothers
did (p = 0.029) in an open-label, prospective study of 88 HBeAg-
positive pregnant women with chronic HBV infection, HBV DNA
levels >6 log10 copies/ml, and increased levels of alanine
aminotransferase.13 Another study of LdT treatment throughout
pregnancy reported that none of 39 of 52 live infants followed up
for more than 6 months and who completed all examinations for
MTIT were found to have HBsAg positivity, indicating a 100%
blocking rate.14 In the present study, the HBV viral load of the
pregnant women who received LdT treatment decreased, whether
during their entire pregnancy or late pregnancy, and the HBsAg and
HBV DNA of all 54 infants were negative, resulting in a 100% HBV
MTIT blocking rate. Furthermore, the HBV vaccination was
successful in infants exposed to LdT in utero, with 98.15% of the
infants protected against hepatitis B and no differences in anti-HBs
titer between the infants exposed to LdT throughout the entire
pregnancy and those exposed only in late pregnancy.
Drug abuse is a primary contributor to birth defects in China.22
The congenital abnormality rates for infants born to mothers
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respectively.18–20 An overall rate of congenital abnormalities of
3.8% (2/53) has been reported in infants whose mothers took LdT
for chronic HBV throughout pregnancy.14 In our study, none of the
infants had abnormal hearing, congenital phenylketonuria, or
hypothyroidism in follow-up periods lasting more than 12 months
and some up to 48 months. Congenital dysplasia was detected in
three cases within the neonatal period, resulting in a congenital
abnormality rate of 5.55%, which is similar to that of women
without or with HBV infection in previous reports.18–20 In addition,
there were no signiﬁcant differences in congenital dysplasia
between children exposed to LdT and the controls. Hemangioma,
abnormal lingual frenulum, and vaginal canal leak were found in
three of our infants, all in the early-pregnancy treatment group.
One patient in the late-pregnancy treatment group had delayed
language abilities without a nervous disorder. No other genetic
metabolic diseases or congenital defects were found. Therefore,
our observations do not support a relationship between LdT
exposure and birth defects or genetic disease; however, additional
large-sample studies are warranted, especially in children exposed
to LdT throughout pregnancy.
The physical development status of the majority of the
neonates was in the normal range at delivery and 6 weeks of
age, as measured by weight and height.23 Moreover, no cases
with growth retardation were observed during the infancy period.
The average height and weight of the infants were higher than
WHO standard values (2006) at 12 months of age, similar to the
ﬁndings presented in a previous report on infants in Beijing.24
Furthermore, the BMI of the infants in our study increased
gradually with age. These observations suggest that LdT treat-
ment in pregnancy does not affect the physical development of
infants.
Follow-up neurodevelopmental assessments in neonates ex-
posed to adverse factors, particularly drugs, are very important
because prenatal exposure can result in abnormal neurological
developmental processes in infants. For example, neonatal
neurobehavioral development is affected by intrauterine low-
level lead exposure,25 and prenatal exposure to elevated levels of
pyrethroid pesticides is associated with reduced neurodevelop-
ment in infants.26 In addition, anti-thyroid treatment during
pregnancy may have adverse effects on the infant’s DQ.27 In the
present study, 84.81% of the overall DQ scores were normal;
however in 17 children, the DQ scores suggested either develop-
mental delay (n = 7) or were suspicious for a developmental delay
(n = 10). Abnormally low scores were spread throughout the GDS
regions, with no dominant abnormal regions. Moreover, there
were no differences between the cases and controls, and the rate of
abnormal scores was similar to that (13.1%) in 2330 infants in a
previous report.28 Therefore, the DQs of children delivered to
chronic HBV-infected women treated with LdT were normal,
suggesting that LdT did not affect the neurodevelopment of these
infants.
However, the combined developmental delay and suspicious
for a developmental delay rates in the present study were higher in
the children prenatally exposed to LdT than the controls. Because
development activity exists along a continuous spectrum in every
child, the ﬁnal developmental assessment results may be normal
for most infants with mildly or moderately delayed development,
especially for those with a marginal status. However, intervention
and follow-up are necessary when infants exposed to LdT during
pregnancy have a lower DQ. Future, larger samples of infants
exposed to LdT throughout pregnancy are necessary to discern any
differences in DQ.
The ﬁndings of the present study indicate that the growth
and development of children of chronic HBV-infected mothers who
are prenatally exposed to LdT are normal, indicating that LdTtreatment increases the HBV MTIT blocking rate but does not
increase the incidence of congenital abnormalities or affect the
physical and neurological development of the infants. LdT
treatment during pregnancy in mothers with chronic hepatitis B
is safe and effective for infants. However, larger sample sizes are
needed in future observations to provide greater insight into the
growth and development of children prenatally exposed to NAs,
including LdT.
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